Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in …
…, AV Kovyrshina, NL Lubenets, DM Grousova… - The Lancet, 2021 - thelancet.com
Background A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac
(Sputnik V), showed a good safety profile and induced strong humoral and cellular immune …
(Sputnik V), showed a good safety profile and induced strong humoral and cellular immune …
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1 …
…, DV Shcheblyakov, AS Dzharullaeva, DM Grousova… - The Lancet, 2020 - thelancet.com
Background We developed a heterologous COVID-19 vaccine consisting of two components,
a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (…
a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (…
[HTML][HTML] Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B. 1.1. 7, B. 1.351, P. 1, B. 1.617. 2, B. 1.617. 3) and Moscow …
…, AV Kovyrshina, AG Botikov, AV Kuzina, DM Grousova… - Vaccines, 2021 - mdpi.com
Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have
been used in mass vaccination companies around the world. Virus neutralization and …
been used in mass vaccination companies around the world. Virus neutralization and …
[HTML][HTML] An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus …
…, NL Lubenets, DM Grousova… - The Lancet Regional …, 2021 - thelancet.com
Background While the world is experiencing another wave of COVID-19 pandemic, global
vaccination program is hampered by an evident shortage in the supply of licensed vaccines. …
vaccination program is hampered by an evident shortage in the supply of licensed vaccines. …
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
…, ME Krasina, EO Bayurova, DM Grousova… - Emerging Microbes & …, 2022 - Taylor & Francis
Although unprecedented efforts aiming to stop the COVID-19 pandemic have been made
over the past two years, SARSCoV-2 virus still continues to cause intolerable health and …
over the past two years, SARSCoV-2 virus still continues to cause intolerable health and …
[HTML][HTML] Retention of neutralizing response against SARS-CoV-2 omicron variant in sputnik V-Vaccinated individuals
D Lapa, DM Grousova, G Matusali, S Meschi… - Vaccines, 2022 - mdpi.com
The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading
all around the world. Omicron has become the dominant variant of SARS-CoV-2. There …
all around the world. Omicron has become the dominant variant of SARS-CoV-2. There …
Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B. 1.1. 529 (Omicron) SARS-CoV-2 variant
…, AS Erokhova, FM Izhaeva, DM Grousova… - medRxiv, 2021 - medrxiv.org
COVID-19 vaccination campaign has been launched around the world. More than 8 billion
vaccines doses have been administered, according to the WHO. Published studies shows …
vaccines doses have been administered, according to the WHO. Published studies shows …
[HTML][HTML] Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an …
…, AS Dzharullaeva, DM Grousova… - Frontiers in …, 2023 - frontiersin.org
To protect young individuals against SARS-CoV-2 infection, we conducted an open-label,
prospective, non-randomised dose-escalation Phase 1/2 clinical trial to evaluate the …
prospective, non-randomised dose-escalation Phase 1/2 clinical trial to evaluate the …
One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the …
…, AV Kovyrshina, NL Lubenets, DM Grousova… - medRxiv, 2021 - medrxiv.org
Objectives Vaccination remains the most effective response to the COVID-19 pandemic. Most
vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, …
vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, …
[HTML][HTML] Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus
…, DI Zrelkin, AS Odintsova, DM Grousova… - Frontiers in …, 2022 - frontiersin.org
WHO has declared the outbreak of monkeypox as a public health emergency of international
concern. In less than three months, monkeypox was detected in more than 30 000 people …
concern. In less than three months, monkeypox was detected in more than 30 000 people …